Sistema de Salut de Catalunya
Institut Català de la Salut
[Gómez-Caamaño A] Radiation Oncology Department, Hospital Clínico Universitario de Santiago de Compostela, A Coruña, Spain. [González-San Segundo C] Radiation Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Henríquez I] Radiation Oncology Department, Hospital Universitario Sant Joan de Reus, Tarragona, Spain. [Maldonado X] Oncologia Radioteràpica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Zapatero A] Radiation Oncology Department, Hospital Universitario de La Princesa, Madrid, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-04-15T07:38:14Z
2021-04-15T07:38:14Z
2019-04
Càncer de pròstata resistent a la castració; Oncologia de les radiacions; Consens
Cáncer de próstata resistente a la castración; Oncología radioterápica; Consenso
Castration-resistant prostate cancer; Radiation oncology; Consensus
Background: The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a lack of or very limited evidence, and clear guidance from clinicians regarding optimal strategy is required. Methods: A modified Delphi method, with 116 relevant questions divided into 7 different CRPC management topics, was used to develop a consensus statement by the URONCOR group. Results: A strong consensus or unanimity was reached on 93% of the proposed questions. The seven topics addressed were: CRPC definition, symptomatic patients, diagnosis of metastasis, CRPC progression, M0 management, M1 management and sequencing therapy, and treatment monitoring. Conclusions: The recommendations based on the radiation oncology experts' opinions are intended to provide cancer specialists with expert guidance and to standardise CRPC patient management in Spain, facilitating decision-making in different clinically relevant issues regarding CRPC patients.
Article
Published version
English
Pròstata - Càncer - Tractament; DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant; Other subheadings::Other subheadings::/therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Clinical Decision-Making; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración; Otros calificadores::Otros calificadores::/terapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::toma de decisiones clínicas
Springer
Clinical and Translational Oncology;21(4)
https://link.springer.com/article/10.1007%2Fs12094-018-1940-2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
